This is a Singapore news story, published by CNBC, that relates primarily to Modulus news.
For more Singapore news, you can click here:
more Singapore newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
French pharmaceutical giant Sanofi. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest evolutive vaccine facility news, Singapore Economic Development Board news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Singapore facilityCNBC
•
79% Informative
Sanofi opens a 800 million Singapore dollar ( $595 million ) "evolutive vaccine facility" in Singapore .
Plant, known as Modulus , can switch between making different vaccines or treatments in a matter of days .
Facility will contribute about 200 skilled jobs to Singapore , and will be fully operational by mid-2026 .
VR Score
87
Informative language
91
Neutral language
76
Article tone
formal
Language
English
Language complexity
66
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links